Clinical Trial

A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 17, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetic profile, and food effect of UA026 tablets. The study consists of four parts: Part A is a single ascending dose (SAD) study, Part B is a multiple ascending dose (MAD) study, Part C is a food effect (FE) study, and Part D is a multi-dose parallel control study. Part A, B, and C will be conducted in healthy subject, and Part D will be conducted in subjects with moderate to severe plaque psoriasis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-17.
Trial Details
NCT Number NCT07038720
Lead Sponsor Usynova Pharmaceuticals Ltd.
Conditions Plaque Psoriasis, Healthy Volunteer
Enrollment 124 participants
Start Date 2025-05-08
Primary Completion 2026-03-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-17